| RS2146822039 |
NPHS1
|
Health Risk |
Likely pathogenic |
— |
| RS2146822068 |
CYBB
|
Health Risk |
Pathogenic |
Granulomatous disease, chronic |
| RS2146822162 |
NPHS1
|
Health Risk |
Likely pathogenic |
— |
| RS2146822164 |
NPHS1
|
Health Risk |
Likely pathogenic |
Finnish congenital nephrotic syndrome, Finnish congenital nephrotic syndrome |
| RS2146822389 |
CEP250
|
Health Risk |
Pathogenic |
— |
| RS2146822662 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2146823207 |
NPHS1
|
Health Risk |
Pathogenic |
— |
| RS2146823273 |
NPHS1
|
Health Risk |
Likely pathogenic |
— |
| RS2146823441 |
NPHS1
|
Health Risk |
Pathogenic |
— |
| RS2146823645 |
NPHS1
|
Health Risk |
Pathogenic |
— |
| RS2146824388 |
NPHS1
|
Health Risk |
Likely pathogenic |
— |
| RS2146826513 |
NPHS1
|
Health Risk |
Pathogenic |
— |
| RS2146827068 |
NPHS1
|
Health Risk |
Pathogenic |
— |
| RS2146827117 |
NPHS1
|
Health Risk |
Likely pathogenic |
— |
| RS2146827686 |
NPHS1
|
Health Risk |
Pathogenic |
Finnish congenital nephrotic syndrome, Finnish congenital nephrotic syndrome |
| RS2146828046 |
NPHS1
|
Health Risk |
Likely pathogenic |
Finnish congenital nephrotic syndrome, Finnish congenital nephrotic syndrome |
| RS2146828438 |
KDM5C
|
Health Risk |
Likely pathogenic |
— |
| RS2146828473 |
NPHS1
|
Health Risk |
Pathogenic |
— |
| RS2146828521 |
NPHS1
|
Health Risk |
Pathogenic/Likely pathogenic |
Finnish congenital nephrotic syndrome, Finnish congenital nephrotic syndrome |
| RS2146828842 |
KDM5C
|
Health Risk |
Pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2146829967 |
NPHS1
|
Health Risk |
Likely pathogenic |
— |
| RS2146830032 |
SHANK3
|
Health Risk |
Likely pathogenic |
— |
| RS2146830385 |
MLC1
|
Health Risk |
Pathogenic |
Megalencephalic leukoencephalopathy with subcortical cysts 1, Megalencephalic leukoencephalopathy with subcortical cysts 1 |
| RS2146830613 |
SHANK3
|
Health Risk |
Pathogenic |
Phelan-McDermid syndrome, Phelan-McDermid syndrome |
| RS2146831183 |
NPHS1
|
Health Risk |
Pathogenic |
— |
| RS2146831207 |
NPHS1
|
Health Risk |
Pathogenic/Likely pathogenic |
Finnish congenital nephrotic syndrome, Finnish congenital nephrotic syndrome |
| RS2146831793 |
SHANK3
|
Health Risk |
Pathogenic |
Phelan-McDermid syndrome, Phelan-McDermid syndrome |
| RS2146831931 |
NPHS1
|
Health Risk |
Pathogenic |
— |
| RS2146831964 |
TMEM94
|
Health Risk |
Pathogenic |
Intellectual developmental disorder with cardiac defects and dysmorphic facies, Intellectual developmental disorder with cardiac defects and dysmorphic facies |
| RS2146832020 |
NPHS1
|
Health Risk |
Pathogenic |
— |
| RS2146832070 |
SHANK3
|
Health Risk |
Pathogenic |
Phelan-McDermid syndrome, Schizophrenia 15 |
| RS2146832176 |
DMD
|
Health Risk |
Pathogenic |
— |
| RS2146832177 |
SHANK3
|
Health Risk |
Pathogenic |
— |
| RS2146832853 |
SHANK3
|
Health Risk |
Likely pathogenic |
Phelan-McDermid syndrome, Phelan-McDermid syndrome |
| RS2146833064 |
SHANK3
|
Health Risk |
Pathogenic |
— |
| RS2146833113 |
KDM5C
|
Health Risk |
Conflicting classifications of pathogenicity |
Syndromic X-linked intellectual disability Claes-Jensen type, Syndromic X-linked intellectual disability Claes-Jensen type |
| RS2146833198 |
DMD
|
Health Risk |
Pathogenic |
Becker muscular dystrophy, Becker muscular dystrophy |
| RS2146833477 |
DMD
|
Health Risk |
Pathogenic |
Abnormality of the musculature, Abnormality of the musculature |
| RS2146833570 |
SHANK3
|
Health Risk |
Pathogenic |
— |
| RS2146833747 |
SHANK3
|
Health Risk |
Likely pathogenic |
Phelan-McDermid syndrome, Phelan-McDermid syndrome |
| RS2146834311 |
NHS
|
Health Risk |
Pathogenic |
Nance-Horan syndrome, Nance-Horan syndrome |
| RS2146834483 |
XK
|
Health Risk |
Pathogenic/Likely pathogenic |
McLeod neuroacanthocytosis syndrome, McLeod neuroacanthocytosis syndrome |
| RS2146834557 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2146834581 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2146834690 |
XK
|
Health Risk |
Pathogenic |
McLeod neuroacanthocytosis syndrome, McLeod neuroacanthocytosis syndrome |
| RS2146836134 |
DMD
|
Health Risk |
Likely pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2146837810 |
KDM5C
|
Health Risk |
Pathogenic |
Spastic paraplegia, Syndromic X-linked intellectual disability Claes-Jensen type |
| RS2146839603 |
KDM5C
|
Health Risk |
Pathogenic |
Syndromic X-linked intellectual disability Claes-Jensen type, Syndromic X-linked intellectual disability Claes-Jensen type |
| RS2146843340 |
SHANK3
|
Health Risk |
Pathogenic |
Neurodevelopmental delay, Neurodevelopmental delay |
| RS2146844008 |
SHANK3
|
Health Risk |
Likely pathogenic |
— |
| RS2146844343 |
KDM5C
|
Health Risk |
Pathogenic |
Syndromic X-linked intellectual disability Claes-Jensen type, Syndromic X-linked intellectual disability Claes-Jensen type |
| RS2146846673 |
ANOS1
|
Health Risk |
Likely pathogenic |
Hypogonadotropic hypogonadism 1 with or without anosmia, Hypogonadotropic hypogonadism 1 with or without anosmia |
| RS2146848829 |
KDM5C
|
Health Risk |
Pathogenic |
— |
| RS2146851322 |
KDM5C
|
Health Risk |
Likely pathogenic |
Syndromic X-linked intellectual disability Claes-Jensen type, Spastic paraplegia |
| RS2146851519 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2146852767 |
KDM5C
|
Health Risk |
Pathogenic |
Syndromic X-linked intellectual disability Claes-Jensen type, Syndromic X-linked intellectual disability Claes-Jensen type |
| RS2146853021 |
KDM5C
|
Health Risk |
Pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2146853282 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2146854677 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2146854993 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2146856395 |
TMPRSS15
|
Health Risk |
Pathogenic |
Enterokinase deficiency, Enterokinase deficiency |
| RS2146858081 |
MLC1
|
Health Risk |
Pathogenic |
— |
| RS2146859220 |
PANK2
|
Health Risk |
Pathogenic |
Pigmentary pallidal degeneration, Pigmentary pallidal degeneration |
| RS2146866687 |
PANK2
|
Health Risk |
Pathogenic |
Pigmentary pallidal degeneration, Pigmentary pallidal degeneration |
| RS2146866795 |
PANK2
|
Health Risk |
Pathogenic |
Pigmentary pallidal degeneration, Pigmentary pallidal degeneration |
| RS2146867849 |
KDM5C
|
Health Risk |
Likely pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2146867887 |
KDM5C
|
Health Risk |
Likely pathogenic |
Syndromic X-linked intellectual disability Claes-Jensen type, Syndromic X-linked intellectual disability Claes-Jensen type |
| RS2146868023 |
KDM5C
|
Health Risk |
Likely pathogenic |
Syndromic X-linked intellectual disability Claes-Jensen type, Syndromic X-linked intellectual disability Claes-Jensen type |
| RS2146868509 |
HUWE1
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2146868820 |
KDM5C
|
Health Risk |
Pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2146869427 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2146869444 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2146871313 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2146871865 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2146872050 |
PANK2
|
Health Risk |
Pathogenic |
Pigmentary pallidal degeneration, Pigmentary pallidal degeneration |
| RS2146872060 |
BCOR
|
Health Risk |
Pathogenic |
Acute myeloid leukemia, Acute myeloid leukemia |
| RS2146872522 |
PANK2
|
Health Risk |
Pathogenic |
Pigmentary pallidal degeneration, Pigmentary pallidal degeneration |
| RS2146873271 |
NF2
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 2 |
| RS2146873791 |
GP6
|
Health Risk |
Pathogenic |
Platelet-type bleeding disorder 11, Platelet-type bleeding disorder 11 |
| RS2146878120 |
HUWE1
|
Health Risk |
Pathogenic |
Intellectual disability, X-linked syndromic |
| RS2146887806 |
PANK2
|
Health Risk |
Pathogenic |
Pigmentary pallidal degeneration, Pigmentary pallidal degeneration |
| RS2146890750 |
BCOR
|
Health Risk |
Likely pathogenic |
BCOR-related disorder, BCOR-related disorder |
| RS2146892080 |
GOSR2
|
Health Risk |
Pathogenic |
Progressive myoclonic epilepsy, Progressive myoclonic epilepsy |
| RS2146892731 |
NF2
|
Health Risk |
Likely pathogenic |
— |
| RS2146892921 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2146894322 |
NF2
|
Health Risk |
Likely pathogenic |
— |
| RS2146894926 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2146895235 |
NF2
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 2 |
| RS2146901330 |
TLK2
|
Health Risk |
Pathogenic |
See cases, See cases |
| RS2146905135 |
MLC1
|
Health Risk |
Pathogenic |
— |
| RS2146908500 |
MLC1
|
Health Risk |
Likely pathogenic |
— |
| RS2146911959 |
GOSR2
|
Health Risk |
Pathogenic |
Progressive myoclonic epilepsy, Progressive myoclonic epilepsy |
| RS2146913390 |
OFD1
|
Health Risk |
Likely pathogenic |
Orofaciodigital syndrome I, Orofaciodigital syndrome I |
| RS2146914606 |
KDM5C
|
Health Risk |
Pathogenic |
Syndromic X-linked intellectual disability Claes-Jensen type, Syndromic X-linked intellectual disability Claes-Jensen type |
| RS2146914735 |
KDM5C
|
Health Risk |
Likely pathogenic |
Syndromic X-linked intellectual disability Claes-Jensen type, Syndromic X-linked intellectual disability Claes-Jensen type |
| RS2146915737 |
KDM5C
|
Health Risk |
Likely pathogenic |
Syndromic X-linked intellectual disability Claes-Jensen type, Syndromic X-linked intellectual disability Claes-Jensen type |
| RS2146915836 |
KDM5C
|
Health Risk |
Likely pathogenic |
Syndromic X-linked intellectual disability Claes-Jensen type, Syndromic X-linked intellectual disability Claes-Jensen type |
| RS2146916049 |
KDM5C
|
Health Risk |
Pathogenic |
— |
| RS2146919105 |
ANOS1
|
Health Risk |
Pathogenic |
Hypogonadotropic hypogonadism 1 with or without anosmia, Hypogonadotropic hypogonadism 1 with or without anosmia |
| RS2146919128 |
ANOS1
|
Health Risk |
Pathogenic |
Hypogonadotropic hypogonadism 1 with or without anosmia, Hypogonadotropic hypogonadism 1 with or without anosmia |